Image

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA)). Patients are followed for 7 months to assess patient satisfaction, safety and clinical outcomes. A qualitative implementation study and a medico-economic evaluation (cost analysis and 5-years budget impact analysis) are embedded to assess acceptability, adoption, feasability, and sustainability and to inform scaling.

Eligibility

Inclusion Criteria:

  • Age ≥ 18 years
  • HCC or iCCA diagnosed according to the criteria of the European Association for the Study of the Liver (2024) or histologically proven.
  • HCC or iCCA naive to intra-arterial treatment. HCC or iCCA may have been previously treated with other non-intra-arterial therapies. Other HCC may have been previously treated but not with intra-arterial therapy.
  • If HCC ou iCCA treatment is proposed at a Multidisciplinary Consultation Meeting (RCP):
  • Patient Child-Pugh \< B8
  • Single or multiple HCC
  • Absence of lobar or truncal portal obstruction
  • Absence of bile duct dilatation
  • If treatment by REH proposed in RCP:
  • Absence of truncal portal tumor invasion
  • Uni-lobar tumor invasion (except for centrohepatic iCCA)
  • Total bilirubin \< 20 mg/l (or 35 µmol/L)
  • Patient affiliated to or benefiting from a social security scheme
  • Patient having signed an informed consent form

Exclusion Criteria:

  • Technical contraindication or morphological elements of predictable technical difficulty
  • Planned combined same day therapeutic strategies at the index procedure (e.g., TACE combined with percutaneous ablation) are not allowed
  • Chronic renal insufficiency (Clairance \< 30 ml/min)
  • Known allergy to a contrast agent or chemotherapy agent
  • inability to participate in ambulatory care (inability to understand and follow discharge instructions, lack of reliable telephone access, absence of a responsible accompanying adult for the first night after discharge, or inability to access urgent care in a timely manner if symptoms occur)
  • Patient previously included in the study
  • Patient who, for psychological, social, family or geographical reasons, could not be regularly monitored, patient who, for psychological, social, family or geographical reasons, could not be followed regularly
  • Concomitant disease or severe uncontrolled clinical situation
  • Severe uncontrolled infection
  • Pregnant, breast-feeding or parturient woman
  • Person deprived of liberty by judicial or administrative decision
  • Person under compulsory psychiatric care
  • Person under a legal protection measure
  • Person unable to give consent

Study details
    Hepato Cellular Carcinoma (HCC)
    Intrahepatic Cholangiocarcinoma

NCT06990659

University Hospital, Angers

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.